BC
SBBP

Boxer Capital’s Strongbridge Biopharma plc. SBBP Stock Holding History

Boxer Capital’s Portfolio SBBP Stock Details SBBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-856,900
Closed -$5.91M – 33
2017
Q3 		$5.91M Sell
856,900
-83,100
-9% -$573K 1.35% 17
2017
Q2 		$6.72M Hold
940,000
– – 1.6% 15
2017
Q1 		$4.46M Hold
940,000
– – 0.98% 17
2016
Q4 		$2.26M Buy
+940,000
New +$3.83M 0.87% 15

Other funds holding SBBP

CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
TAF
Tredje AP-fonden Se-111 91 Stockholm, Sweden $18.3B AUM 27.14% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

Boxer Capital's SBBP Position: Q4 2017 in Review

Boxer Capital sold out of Strongbridge Biopharma plc. (SBBP) in Q4 2017, closing a stake of 856,900 shares — an estimated $5.91M sold.

Boxer Capital first reported a position in SBBP in Q4 2016 and held it in 4 quarters. The position peaked at $6.72M in Q2 2017. 54 funds tracked by Wall St. Rank hold SBBP as of Q4 2017.

  • Boxer Capital reported no remaining Strongbridge Biopharma plc. position as of Q4 2017 after selling out during the quarter.
  • Boxer Capital sold 856,900 Strongbridge Biopharma plc. shares in Q4 2017, an estimated $5.91M.
  • Boxer Capital first reported a position in Strongbridge Biopharma plc. in Q4 2016 and held it in 4 quarters.
  • Boxer Capital's Strongbridge Biopharma plc. position peaked at $6.72M in Q2 2017.
  • 54 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q4 2017.

Based on Boxer Capital's 13F filing for Q4 2017, filed 14 Feb 2018.